{"id":"bbr-3464","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL119296","moleculeType":"Small molecule","molecularWeight":"102.18"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BBR 3464 works by selectively inhibiting the PI3K delta subunit, which is involved in the activation of immune cells. This inhibition leads to a reduction in the activity of these cells, resulting in a decrease in inflammation and potentially reducing the severity of autoimmune diseases.","oneSentence":"BBR 3464 is a small molecule inhibitor of the PI3K delta subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:19.110Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT00024362","phase":"PHASE2","title":"BBR 3464 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot be Treated With Surgery","status":"UNKNOWN","sponsor":"Theradex","startDate":"2001-05","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT00014547","phase":"PHASE2","title":"BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment","status":"UNKNOWN","sponsor":"Theradex","startDate":"2000-11","conditions":"Lung Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BBR 3464","genericName":"BBR 3464","companyName":"Theradex","companyId":"theradex","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BBR 3464 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsing multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}